Figure 6 | Scientific Reports

Figure 6

From: Molecular subtyping of glioblastoma based on immune-related genes for prognosis

Figure 6

Clinical practice application of the prognostic predictor. (A) OS curves of the two clusters predicted from 24 GBM patients using the prognosis model. The log-rank test was used to assess the statistical significance of the difference. The red line indicates the Risk-H group, while the blue line indicates the Risk-L group, based on the median RiskScore value. (B) ROC curve with AUC under the final prognostic predictor. (C) Relationship between the RiskScore value and the score of CD3+CD4+/CD3+CD8+ cells of the peripheral blood samples of 24 GBM patients. The RiskScore value was negatively associated with the ratio of CD3+CD4+/CD3+CD8+ cells. (D) Relationship between the RiskScore value and the percentage of CD4+CD25+ Tregs in peripheral blood samples of the 24 GBM patients. The RiskScore value was positively related with the percentage of CD4+CD25+ Tregs. (E) Immunohistochemical (IHC) analysis of PD-L1 (left) and PD-L2 (right) for the 24 GBM patients. (F) Relationship between the IHC score of PD-L1 (yellow) or PD-L2 (green) and the RiskScore groups. The IHC score was positively correlated with the RiskScore value.

Back to article page